Compare VanEck Gold Miners ETF (GDX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs State Street SPDR S&P Biotech ETF — how do they compare? VanEck Gold Miners ETF trades at $89.29 (market cap $25.65B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: VanEck Gold Miners ETF is far larger — about 2.5× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GDX | XBI | |
|---|---|---|
Market Cap | $25.65B | $10.11B |
Volume | 16,534,046 | 12,903,266 |
52-Week High | $115.84 | $169.55 |
52-Week Low | $68.28 | $104.99 |
Typical Hold Time | 76 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX, the VanEck Gold Miners ETF, trades at $89.28, up 4.47% over 24 hours but remains in a bearish technical trend with key resistance at $89. The fund provides exposure to gold mining equities, though specific financial ratios are not available in the provided data. Recent news highlights institutional selling and comparisons between gold miners and physical gold investments.
The outlook for GDX is mixed, with technical indicators signaling caution but potential for gains if gold prices rise. Risks include sensitivity to gold prices, interest rate changes, and miner operational issues. Opportunities exist if macroeconomic factors boost gold demand, but volatility is a key concern for investors.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
